Acromegaly is an endocrine disorder caused by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels[1] Signifor LAR (pasireotide) represents a potential new option for ...
Clinicians who treat patients with acromegaly commonly show a lack of awareness of the severity and pattern of patient symptoms that can occur even when treatment suggests the condition is under ...
Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of the New Drug Application (NDA) for Oclaiz™ (CAM2029), ...
EAST HANOVER, N.J., May 5, 2014 /PRNewswire/ -- Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor ® LAR (pasireotide LAR; SOM230) in patients with ...
October 13, 2010 (Liege, Belgium) — In patients with treatment-resistant, active acromegaly, normalizing insulin-like growth factor 1 (IGF-1) levels leads to a marked reduction in cardiovascular risk, ...
The FDA has approved an oral treatment to help people diagnosed with a rare overgrowth disease. Oregon resident, Stacey Hardin says news about the therapeutic advancement is “huge” and could mean an ...
Please provide your email address to receive an email when new articles are posted on . Adults with acromegaly are more likely to have hypertension, diabetes and other comorbidities than healthy ...
NEEDHAM, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize ...
Oclaiz is a subcutaneous long-acting octreotid depot, designed for optimized disease control and convenient self-administration. The product is based on Camurus' FluidCrystal technology and is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback